The claim is early, and the funding backdrop is shaky
The most AI-specific development in this period is also the least documented. Radical Numerics says AI-designed viruses have treated the startup's first patient, with an experimental treatment aimed at drug-resistant E. coli.1 That is a company statement relayed in a newsletter. Our dossier holds no trial data, patient numbers or outcomes for it. Via News's narrative tracking also flags an AI agent that carried out a brain injection, but the dossier carries no source document with details. We will not characterise it beyond that.2
The source matters here. The newsletter that carried the Radical Numerics claim has a measured reliability of 6%: of 16 claims we checked from that publication's feed, about 6% held up.1 That does not make the claim false. It does mean readers should treat it as a company's account, not an established result.
The money side weakened in the same fortnight
On October 30, 2026, a $1 trillion tech selloff deepened fears of an AI bubble. Heavy AI spending and weak earnings spooked investors, and the Nasdaq 100 had its worst day since June.3 A trillion dollars is a thousand billion. The next day, OpenAI cut its funding target by $10 billion.4 On November 1, Binance users withdrew $3.6 billion when the exchange reopened after a hack.5
To picture the scale, compare Incyte, a mid-sized drug developer. Its verified cash at the end of Q3 2026 was about $3.28 billion.6 The Binance withdrawals were therefore roughly Incyte's entire cash pile in a few days. OpenAI's $10 billion cut is about three times that pile.
Binance is a crypto exchange, not an AI company, and the dossier does not link its withdrawals to AI funding. Via News's analysis treats these events as one mood: investors are less willing to fund expensive bets. That is our reading of the timing, not a documented causal chain. Our narrative tracking labels the picture a divergence with mixed sentiment: clinical progress continues while the financial backdrop weakens.2
Conventional biotech is showing checkable progress
The strongest evidence in the period has nothing to do with AI. Vor Bio announced final two-year Phase 3 TELIGAN results for telitacicept in IgA nephropathy, a kidney disease, on October 22, 2026. The treated group's kidney function declined at an annualized eGFR slope of -0.6, against -5.7 mL/min/1.73 m² per year for placebo. That is a 5.1 difference (p<0.001). The company also reports 89% and 81% reductions in the risk of confirmed 30% and 40% declines in eGFR. It says proteinuria reductions held through 104 weeks and that safety was favorable.7 These are company-reported figures from a press release. That source family is rated 54% reliable across 6,613 checked claims, so the numbers deserve independent confirmation.7
Our narrative tracking also points to Incyte's ESMO pancreatic cancer data and partnerships, and to strong Eli Lilly GLP-1 demand.2 The dossier holds no source document for either. The Incyte items we can check are its filings.
What Incyte's verified numbers show
Incyte's cash has swung widely and is now high. It was $3.21 billion at the end of FY 2023, fell to $1.69 billion at the end of FY 2024, and reached $3.10 billion at the end of FY 2025.6 Quarterly cash then went $3.46 billion in Q1 2026, $3.98 billion in Q2 and $3.28 billion in Q3.6 The Q3 figure is about $0.7 billion below Q2. The dossier does not say why, and we will not guess.
The cost of producing its sales is rising modestly. Cost of revenue was $108.7 million in Q3 2026, against $99.0 million in Q3 2025, roughly 10% more.8 For the full year it rose from $255.0 million in FY 2023 to $312.1 million in FY 2024 and $372.1 million in FY 2025.8
One oddity in the verified data: capital spending is listed at exactly $48.7 million for both FY 2024 and FY 2025.9 Identical figures in consecutive years can be coincidence or a data artifact. Both are marked canonical from SEC filings, but we would check the filings before drawing conclusions from the match.
Pipelines are giving dates, and some are now due
Small developers are publishing timelines, which is where the capital question bites. Ernexa Therapeutics said it remained on schedule to submit its IND application for ERNA-101 in Q3 2026, with a first-in-human Phase 1 trial expected in Q4 2026.10 Prelude Therapeutics expected an IND for PRT13722 by mid-2026 and a Phase 1 study in ER-positive breast cancer in the second half of 2026.11 Akari Therapeutics' CEO pointed to ADC-refractory patients as a growing unmet need and an exclusive opportunity for its novel payload. Akari's planned Phase 1 is mid-2027.12 The dossier does not say whether Ernexa or Prelude met these dates. Companies that fall behind are the ones most exposed if funding tightens.
Companies are also hiring. Idorsia appointed Begoña Carreño-Gómez as Chief Business Development Officer, effective November 1, 2026.13 Hiring a dealmaker is a sign of confidence in partnering. It is not proof that partnering money will arrive.
Claims that need a hard look
Generation Lab says its treatment "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues."14 That is the company's own fact-sheet language. The MIT Technology Review piece that reported it carries the same low 6% reliability rating as the newsletters above.14 The dossier contains no clinical evidence for the claim. We cite it to show the kind of language the sector produces, not to endorse it.
What to watch
- Whether Radical Numerics publishes patient-level results for its E. coli treatment. Until then it is a company claim.
- Whether Ernexa's IND filing and Phase 1 start landed on schedule, and whether Prelude's did.
- Incyte's next quarterly cash figure, against $3.28 billion in Q3 2026.
- Whether OpenAI's lower target and the tech selloff spread into funding for AI-linked biotech. Nothing in our data shows that yet.

